



AOCC2025, The 13th Annual Meeting of Asian Organization for Crohn's & Colitis Morning Seminar 1

Date July 11, 2025 8:00-8:50

Venue Room I, Convention Hall A
Makuhari Messe - International Conference Hall
2-1 Nakase, Mihama-ku, Chiba-shi, Chiba 261-8550, Japan

Facilitator

Professor Tadakazu Hisamatsu, M.D., Ph.D.

Department of Gastroenterology and Hepatology, Kyorin University School of Medicine

Session

Expanding Horizons in Inflammatory Bowel Disease with Skyrizi as a First- Line Biologic for CD

Performer

Dr. Kazuhiko Uchiyama

Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine

INDICATIONS AND USAGE

SKYRIZI 600 mg vial: For the induction therapy, SKYRIZI indicated for the treatment of moderately to severely active Crohn's disease in adults who have had an inadequate response to, lost response to, or were intolerant to conventional therapies.

SKYRIZI 180mg/360 mg prefilled cartridge: For the maintenance therapy, SKYRIZI indicated for the treatment of moderately to severely active Crohn's disease in adults who have had an inadequate response to, lost response to, or were intolerant to conventional therapies.

Co-host by AOCC2025, The 13th Annual Meeting of Asian Organization
for Crohn's & Colitis and AbbVie GK

